First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
copanlisib (BAY 80-6946) 是一种静脉注射的泛 I 类磷脂酰肌醇 3-激酶抑制剂，用于治疗晚期实体瘤和非霍奇金淋巴瘤患者，这是首次人体 I 期研究。
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw282
Patnaik, A; Appleman, L J; Tolcher, A W; Papadopoulos, K P; Beeram, M; Rasco, D W; Weiss, G J; Sachdev, J C; Chadha, M; Fulk, M; Ejadi, S; Mountz, J M; Lotze, M T; Toledo, F G S; Chu, E; Jeffers, M; Peña, C; Xia, C; Reif, S; Genvresse, I; Ramanathan, R K
